Levosimendan

Levosimendan, the active ingredient in Levosimendan, is a calcium sensitizer and ATP‑sensitive potassium‑channel opener presented as an injectable solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock, providing inotropic support and vasodilation for hospitalized patients when standard therapies are inadequate.

GNH USA supplies Levosimendan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide. Our distribution network ensures regulatory‑approved quality and reliable cold‑chain logistics for this injectable product.

Levosimendan is used in acute heart‑failure syndromes where enhanced contractility and vasodilation are required. - Acute decompensated heart failure: increases myocardial contractility and reduces preload and afterload, leading to improved cardiac output and relief of pulmonary edema. - Cardiogenic shock: delivers inotropic support and systemic vasodilation, helping to restore organ perfusion when standard catecholamines are inadequate. - Post‑cardiac surgery low‑output syndrome: stabilises haemodynamics by enhancing contractility without raising intracellular calcium, aiding early recovery in intensive‑care patients.

Levosimendan may be associated with several adverse reactions, ranging from frequent, mild events to rare but serious complications. Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional, may be related to infusion rate. - Hypotension: drop in blood pressure due to vasodilation. - Arrhythmias: ventricular ectopy or tachycardia observed in some patients. Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring vasopressor support. - Ventricular tachycardia/fibrillation: life‑threatening rhythm disturbances. - Allergic reactions: anaphylaxis or severe skin rash.

When using Levosimendan, clinicians should observe specific precautions to minimise risk and ensure optimal therapeutic benefit. - Cardiovascular monitoring: continuous blood pressure and ECG monitoring during infusion. - Concomitant vasodilators: avoid or reduce dose of other vasodilators to prevent excessive hypotension. - Renal impairment: adjust infusion rate and monitor renal function closely. - Hepatic dysfunction: use with caution; monitor liver enzymes. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety profile. Major Interactions (Avoid): - Strong vasodilators (e.g., nitroglycerin, hydralazine): may cause severe hypotension. - Potassium channel blockers (e.g., glibenclamide): can diminish the drug’s vasodilatory effect. Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response, requiring dose adjustment. - Calcium channel blockers: additive effects on vascular tone, monitor blood pressure. - Diuretics: may enhance volume depletion, watch electrolytes.